A
Acclarent
New technologies to treat patients suffering from ent disorders
About Acclarent
Acclarent, a subsidiary of Johnson & Johnson Medical Devices Companies, specializes in developing minimally invasive ear, nose, and throat (ENT) solutions. The company primarily serves healthcare providers, including hospitals and specialized ENT clinics, by offering advanced medical devices designed to improve patient outcomes and streamline surgical procedures. Operating within the medical device industry, Acclarent focuses on innovation and the integration of cutting-edge technology to address common ENT issues such as chronic sinusitis and Eustachian tube dysfunction. The business model revolves around the research, development, and commercialization of these specialized devices, generating revenue through the sale of its products to medical institutions and practitioners. Acclarent leverages Johnson & Johnson's extensive distribution network and expertise in medical technology to maintain a competitive edge in the market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2004
- Headquarters
- Menlo Park, United States
- Employees
- 185
- Open positions
- None listed
- Dealroom signal
- 63.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Surgery, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company
- Capital deployed
- —
- Preferred round
- Unknown
Latest news
Press, funding announcements and product moves mentioning Acclarent.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2023 | $275M | — | Integra LifeSciences | ↗ |
| ACQUISITIONOther financing | Dec 2009 | $785M | $785M | Johnson & Johnson | — |
Growth signals
Latest recorded traffic for Acclarent is 140 monthly website visits, down 81.8% over the last three months. Acclarent's team declined 37.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
ExploraMed
Series A2 investors entered at this stage
Series B and later3 investors entered at this stage
Meritech Capital
Delphi Ventures
Johnson & Johnson Development Corporation
Other known investors3 additional known investors
Integra LifeSciences
Johnson & Johnson
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acclarent on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acclarent’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.